/

IRWD

Ironwood Pharmaceuticals, Inc.After hours

3.60+0.01 +0.28%USD

NasdaqGS · as of Oct 14, 16:00 ET · 15m delayAfter hours 3.57 −0.83%

Open

3.55

Prev close

3.59

Day range

3.513.63

52-week range

1.435.78

Volume

1.22M0.62×

Mkt cap

594.86M

P/E ttm

4.68

Fwd P/E

2.40

EPS ttm

0.7700

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−37.72%

Price Chart

Yahoo Finance · delayed

IRWDOct 14, 2026O 3.55H 3.63L 3.51C 3.60+0.01 (+0.28%)Vol 1.22M

SMA 504.12
SMA 2004.02

1Y change +143.24% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IRWD Ironwood Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.00%
1 month: −13.67%
3 months: −10.00%
6 months: −17.62%
Year to date: +6.82%
1 year: +143.24%

Valuation & ownership

Market cap: 594.86M
Enterprise value: 912.60M
P/E (ttm): 4.68
Forward P/E: 2.40
PEG ratio: —
Price / book: —
Price / sales (ttm): 1.53
EV / EBITDA: 3.83
EPS (ttm): 0.7700
EPS (forward): 1.50
Beta (5y monthly): 0.22
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 165.24M
Float: 136.76M
Short % of float: 10.29%
Short ratio (days): 7.79
Held by insiders: 3.24%
Held by institutions: 99.04%
Avg volume (3m): 1.98M
50-day average: 4.14
200-day average: 4.01
52-week change: +143.24%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 36.5
vs 50-day SMA: −12.64%
vs 200-day SMA: −10.35%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.27%
Realised vol (20d, ann.): 45.9%
From 52-week high: −37.72%
From 52-week low: +151.75%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

6.10

+69.44% implied

Low 3.70Median 5.35High 10.00

Recommendation trend

Now2 / 2 / 0
1m ago2 / 2 / 0

DES

About Ironwood Pharmaceuticals, Inc.

Yahoo Finance profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 100
Headquarters: Boston, MA, United States
Website: ironwoodpharma.com
Officers: Mr. Thomas A. McCourt CEO & Director
Ms. Tammi Gaskins

SEAS

Seasonality · IRWD

2010–2026 · monthly returns

Strongest month Nov +9.86%Weakest month Apr −5.33%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	45.1	-30.1	2.6	17.7	-13.6	17.9	0.5	0.5	-6.6	-9.3			+6.8%
2025	-47.2	-31.2	-8.7	-36.7	-35.5	20.0	5.6	73.7	-0.8	46.6	82.3	-3.7	−23.9%
2024	24.0	-33.5	-7.6	-11.0	-18.7	3.5	4.8	-25.9	-18.6	-4.1	-10.9	25.9	−61.3%
2023	-7.0	-2.2	-6.7	-1.0	4.5	-2.2	4.2	-20.6	9.4	-6.9	10.4	15.6	−7.7%
2022	-4.4	-3.5	16.9	-4.6	-6.1	2.3	-0.7	-6.0	-3.7	5.6	10.7	2.3	+6.3%
2021	-10.3	-9.7	21.1	-1.3	4.8	11.2	3.1	-1.3	-0.3	-2.2	-13.2	5.1	+2.4%
2020	-9.2	-0.3	-16.2	-0.9	-2.7	6.1	-11.1	10.1	-11.0	9.9	16.6	-1.1	−14.4%
2019	31.9	4.2	-5.0	4.9	-8.1	0.1	-2.8	-12.4	-7.7	16.9	19.7	10.7	+53.4%
2018	-1.2	-4.1	8.7	17.4	2.5	2.9	0.8	-0.2	-4.1	-29.0	5.5	-25.0	−30.9%
2017	-6.0	17.5	1.0	-4.3	8.5	6.6	-6.0	-10.1	-1.1	-2.5	12.3	-13.2	−2.0%
2016	-20.4	4.6	13.4	-4.5	19.5	4.7	8.0	-5.6	19.0	-19.6	22.2	-2.0	+31.9%
2015	1.7	-0.8	3.6	-14.6	3.3	-14.5	-13.3	5.3	-5.3	9.0	7.4	-5.0	−24.3%
2014	19.5	4.6	-15.1	-10.6	29.9	7.1	-3.5	-12.6	0.2	8.2	-1.3	10.7	+32.0%
2013	15.7	16.5	22.5	-16.8	-12.2	-25.6	23.3	-4.8	1.6	-18.8	18.8	1.7	+4.8%
2012	25.1	-10.6	-0.6	-0.8	-9.8	15.6	-6.6	-2.6	2.0	-9.0	-7.1	2.6	−7.4%
2011	4.3	13.3	14.3	4.6	3.4	4.0	-4.9	-14.8	-15.2	25.9	-11.2	-0.8	+15.7%
2010			4.8	-5.1	-9.1	1.5	-1.0	-21.4	9.8	9.9	-4.5	-3.2	−20.4%

INSD

Insider Activity · IRWD

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

610.5K shares

Sells, 6 months

149.5K shares

Net shares

+461K

Net change in insider shares

+9.40%

Date	Insider	Transaction	Shares	Value
Jul 19, 2026	Silber Jeffrey M.D.Officer	Stock Award(Grant) at price 0.00 per share.	137K	—
Jul 6, 2026	Silver RonaldOfficer	Sale at price 4.52 per share.	127.9K	$578.06K
Jun 15, 2026	Shepard Jay P.Director	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Duane Jon RDirector	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Denner Alexander JDirector	Stock Award(Grant) at price 0.00 per share.	67.5K	—
Jun 15, 2026	Currie Mark GDirector	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Mchugh Julie HDirector	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Kessler Marla LDirector	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Moukheibir CatherineDirector	Stock Award(Grant) at price 0.00 per share.	63.5K	—
Jun 15, 2026	Mchugh Julie HDirector	Sale at price 3.73 per share.	21.6K	$80.46K
May 18, 2026	Silver RonaldChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	25K	—
Mar 16, 2026	Denner Alexander JDirector	Sale at price 3.05 - 3.31 per share.	6.73M	$20.53M
Mar 12, 2026	Denner Alexander JDirector	Stock Award(Grant) at price 0.00 per share.	4.5K	—
Mar 9, 2026	Shetzline MichaelOfficer	Stock Award(Grant) at price 0.00 per share.	136.6K	—
Mar 9, 2026	Silver RonaldOfficer	Stock Award(Grant) at price 0.00 per share.	163.9K	—
Mar 9, 2026	Minardo JohnOfficer	Stock Award(Grant) at price 0.00 per share.	136.6K	—
Mar 9, 2026	Martini Gregory S.Chief Financial Officer	Stock Award(Grant) at price 0.00 per share.	136.6K	—
Mar 9, 2026	Gaskins Tammi LOfficer	Stock Award(Grant) at price 0.00 per share.	136.6K	—
Mar 9, 2026	Mccourt Thomas AChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	409.8K	—
Feb 23, 2026	Shetzline MichaelOfficer	Sale at price 3.66 - 3.81 per share.	32.6K	$121.59K

13F

Investors Holding IRWD

latest 13F filings of 29 followed managers

Investors holding IRWD
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$33.7M	0.05%	7.99M	−0.8%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IRWD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IRWD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ironwood Pharmaceuticals, Inc.

Seasonality · IRWD

Insider Activity · IRWD

Congress Trades · IRWD

Investors Holding IRWD

Investors Holding IRWD

Congress Trades · IRWD

Insider Activity · IRWD

Seasonality · IRWD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ironwood Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News